Advertisement
Advertisement
U.S. Markets open in 2 hrs 56 mins
Advertisement
Advertisement
Advertisement
Advertisement

Tetra Bio-Pharma Inc. (TBPMF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1864-0.0040 (-2.10%)
At close: 3:57PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1904
Open0.1902
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1801 - 0.1902
52 Week Range0.1110 - 0.4400
Volume81,521
Avg. Volume238,534
Market Cap72.575M
Beta (5Y Monthly)2.14
PE Ratio (TTM)N/A
EPS (TTM)-0.0920
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Tetra Bio-Pharma Provides Update on Clinical Development Program for QIXLEEF™

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today provided an update on the progress and significant achievements of its lead investigational drug, QIXLEEF™.

  • PR Newswire

    REDUVO™ - A Major Milestone for Tetra Bio-Pharma Inc.

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today that numerous pre-launch activities for REDUVO™ have been initiated. REDUVO™ is a cannabinoid-derived drug indicated in chemotherapy-induced nausea and vomiting (CINV). In December 2020, the Company submitted a New Drug Submission to Health Canada which is currently in its final stage of review by the regulator.

  • PR Newswire

    Tetra Bio-Pharma Receives Positive Scientific Advice Assessment (SAA) Report for QIXLEEF™

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development is pleased to announce that it received the Scientific Advice Assessment (SAA) Report from the Malta Medicines Authority. Overall, the SAA Report provided positive feedback on Tetra's drug development plan for QIXLEEF™ and eligibility for submitting a Marketing Authorization Application (MAA) under Directive 2001/83/EC (Directive). QIXLEEF™ is the

Advertisement
Advertisement